Development of the first inhaled antibiotic for the treatment of cystic fibrosis

• Published in: Science translational medicine Vol. 2; no. 63; p. 63mr4
• Main Authors: Rose, Lynn M, Neale, Richard
• Format: Journal Article
• Language: English
• Published: United States 22.12.2010
• Subjects: Administration, Inhalation; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - therapeutic use; Cystic Fibrosis - drug therapy; Humans; Tobramycin - administration & dosage; Tobramycin - therapeutic use; United States; United States Food and Drug Administration; United States
• ISSN: 1946-6242
• DOI: 10.1126/scitranslmed.3001634

Tobramycin Inhalation Solution USP (TOBI), a therapy developed to treat lung infections associated with cystic fibrosis (CF), was presented as a demonstration case for collaborative pharmaceutical development at a Clinical and Translational Science Awards Industry Forum on "Promoting Efficient and Effective Collaborations Among Academia, Government, and Industry" held in February 2010. TOBI was developed by PathoGenesis Corporation (Seattle, WA) in collaboration with the academic inventors, the National Institutes of Health, the U.S. Food and Drug Administration, and the CF Foundation. The presenters, representing the academic, industry, and foundation partners, each reviewed the program from their perspectives and identified challenges that existed during the discovery, development, and commercialization of TOBI. The attendees were asked to consider other collaborative opportunities that might have further improved TOBI development, including the optimal roles of the academic researchers, foundations, and other agencies when industry drives development and commercialization decisions.